GI INNOVATION

GI INNOVATION

GI Innovation is a global leader of microbiome drug development.

HQ location
Munjeong-dong, South Korea
Launch date
Employees
Enterprise value
$573—859m
Company register number
6828600771
  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
investor investor investor investor investor

€0.0

round
N/A

$206m

IPO
Total Funding000k
Notes (0)
More about GI INNOVATION
Made with AI
Edit

GI Innovation is a bio venture company focused on the research and development of innovative protein-based drugs. The company operates in the biotechnology sector, serving patients worldwide by creating new bio drugs through structured translational research. GI Innovation leverages its proprietary platform, which includes high throughput screening systems and bispecific antibody programs, to efficiently discover and develop lead products and cell lines. The company primarily targets the global healthcare market, aiming to address unmet medical needs with its novel therapeutic solutions. Its business model revolves around the development and commercialization of patented substances, ensuring exclusive rights to their innovative drugs. Revenue is generated through the sale of these proprietary drugs and potential licensing agreements with other pharmaceutical companies. Key clients include healthcare providers, research institutions, and pharmaceutical companies looking for cutting-edge bio drug solutions.

Keywords: biotechnology, protein-based drugs, translational research, high throughput screening, bispecific antibodies, global healthcare, innovative therapeutics, patented substances, commercialization, pharmaceutical partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo